Drug Profile
Levodopa intranasal - Impel Pharmaceuticals
Alternative Names: INP103; POD™ levodopaLatest Information Update: 27 Apr 2022
Price :
$50
*
At a glance
- Originator Impel NeuroPharma
- Developer Impel Pharmaceuticals
- Class Antiasthmatics; Antiparkinsonians; Catecholamines; Small molecules
- Mechanism of Action Dopamine D1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Parkinson's disease
Most Recent Events
- 25 Apr 2022 Impel Neuropharma is now called Impel Pharmaceuticals
- 07 Apr 2021 Levodopa intranasal is still in phase II trials for Parkinson's disease in Australia
- 11 Jun 2019 Impel NeuroPharma completes the phase IIa THOR 201 in Parkinson’s disease in Australia (Intranasal) (NCT03541356) (ACTRN12618000427279)